Mayo Clinic | Strategic Alliance Partners

February 20, 2024

A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.

February 16, 2024

Jacob Shreve, MD, discusses the potential impact of implementing artificial intelligence into cancer care.

February 16, 2024

Pooja Advani, MBBS, MD, discusses the use of ribociclib plus endocrine therapy for patients with hormone receptor–positive, HER2– breast cancer.

February 14, 2024

Ricardo D. Parrondo, MD, discusses the phase 1b/2 RedirecTT-1 of teclistamab and talquetamab in relapsed/refractory multiple myeloma.

February 14, 2024

Pooja Advani, MBBS, MD, discusses the advantages of using liquid biopsy in metastatic breast cancer.

February 13, 2024

A panel of experts discuss how to sequence BTK inhibitors and CAR T-cell therapies in patients with MCL.

February 13, 2024

Experts on mantle cell lymphoma discuss third-line treatment options available for patients.

February 10, 2024

Pooja Advani, MBBS, MD, discusses key advancements that have occurred for the treatment of patients with triple-negative breast cancer.

February 07, 2024

Ricardo D. Parrondo, MD, discusses the exploration of the non-BCMA CAR T-cell target GPRC5D in multiple myeloma.

February 07, 2024

Talha Badar, MBBS, MD, discusses key efficacy data with imetelstat from the phase 2/3 IMerge trial of patients with lower-risk myelodysplastic syndrome.

February 06, 2024

Experts on mantle cell lymphoma discuss second-line treatment options available for patients.

February 06, 2024

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.

January 30, 2024

Talha Badar, MBBS, MD, discusses the FDA approval of ivosidenib for patients with myelodysplastic syndrome and the future management of this disease.

January 30, 2024

Experts on mantle cell lymphoma discuss first-line treatment options available for patients.

January 30, 2024

Laurie Sehn, MD, and Bijal Shah, MD, discuss remaining unmet needs for patients with relapsed/refractory FL.

January 24, 2024

Talha Badar, MBBS, MD, discusses myelodysplastic syndrome risk stratification and the FDA approval of luspatercept for patients with this disease.

January 23, 2024

Peter Martin, MD, discusses how to sequence bispecific T-cell engagers and CAR T-cell therapies in the third-line and beyond setting for FL.

January 23, 2024

Jennifer Crombie, MD, discusses how to choose CAR T-cells as third-line and beyond therapy for FL.

January 23, 2024

Pooja Advani, MBBS, MD, discusses the potential utilization of capivasertib plus fulvestrant in hormone receptor–positive, HER2-negative breast cancers with PIK3/AKT/PTEN pathway alterations.

January 17, 2024

As novel drugs targeting the AURKA pathway continue to advance through the development pipeline, alisertib has emerged as an agent of particular note.